JP2018503600A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503600A5
JP2018503600A5 JP2017526592A JP2017526592A JP2018503600A5 JP 2018503600 A5 JP2018503600 A5 JP 2018503600A5 JP 2017526592 A JP2017526592 A JP 2017526592A JP 2017526592 A JP2017526592 A JP 2017526592A JP 2018503600 A5 JP2018503600 A5 JP 2018503600A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503600A (ja
JP6951973B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060287 external-priority patent/WO2016077526A1/en
Publication of JP2018503600A publication Critical patent/JP2018503600A/ja
Publication of JP2018503600A5 publication Critical patent/JP2018503600A5/ja
Priority to JP2021066180A priority Critical patent/JP2021118699A/ja
Application granted granted Critical
Publication of JP6951973B2 publication Critical patent/JP6951973B2/ja
Priority to JP2023034165A priority patent/JP2023063357A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526592A 2014-11-12 2015-11-12 グリカン相互作用化合物及び使用方法 Active JP6951973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021066180A JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462078610P 2014-11-12 2014-11-12
US62/078,610 2014-11-12
US201562102527P 2015-01-12 2015-01-12
US62/102,527 2015-01-12
US201562145214P 2015-04-09 2015-04-09
US62/145,214 2015-04-09
US201562173560P 2015-06-10 2015-06-10
US62/173,560 2015-06-10
US201562187587P 2015-07-01 2015-07-01
US62/187,587 2015-07-01
PCT/US2015/060287 WO2016077526A1 (en) 2014-11-12 2015-11-12 Glycan-interacting compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021066180A Division JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2018503600A JP2018503600A (ja) 2018-02-08
JP2018503600A5 true JP2018503600A5 (enExample) 2020-07-02
JP6951973B2 JP6951973B2 (ja) 2021-10-20

Family

ID=55955018

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526592A Active JP6951973B2 (ja) 2014-11-12 2015-11-12 グリカン相互作用化合物及び使用方法
JP2021066180A Pending JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A Pending JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021066180A Pending JP2021118699A (ja) 2014-11-12 2021-04-09 グリカン相互作用化合物及び使用方法
JP2023034165A Pending JP2023063357A (ja) 2014-11-12 2023-03-07 グリカン相互作用化合物及び使用方法

Country Status (15)

Country Link
US (4) US20170306046A1 (enExample)
EP (2) EP4183806A3 (enExample)
JP (3) JP6951973B2 (enExample)
CA (1) CA2967595A1 (enExample)
CY (1) CY1125977T1 (enExample)
DK (1) DK3218005T5 (enExample)
ES (1) ES2941897T3 (enExample)
FI (1) FI3218005T3 (enExample)
HU (1) HUE061672T2 (enExample)
IL (3) IL278574B2 (enExample)
MX (2) MX2017006167A (enExample)
PL (1) PL3218005T3 (enExample)
PT (1) PT3218005T (enExample)
SI (1) SI3218005T1 (enExample)
WO (1) WO2016077526A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2016257721B2 (en) 2015-05-01 2019-11-14 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
US20200041517A1 (en) * 2015-06-12 2020-02-06 Seattle Genetics, Inc. Compositions and methods for targeting cancer stem cells
CN108463248B (zh) * 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3541847A4 (en) * 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018119518A1 (en) * 2017-01-01 2018-07-05 Lee Chi Yu Gregory Rp215 chimeric antigen receptor construct and methods of making and using same
WO2018144769A1 (en) * 2017-02-02 2018-08-09 The Scripps Research Institute Engineered cells and methods of use
EP3589319A4 (en) * 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
US12552874B2 (en) 2019-11-26 2026-02-17 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
US20230058044A1 (en) * 2019-11-26 2023-02-23 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
US20240043561A1 (en) * 2020-11-24 2024-02-08 Ramot At Tel-Aviv University Ltd. Humanized antibodies and fragments thereof binding to carbohydrate antigens and uses thereof
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
US12406510B2 (en) * 2021-03-26 2025-09-02 Howard University Method for the detection, segmentation and morphological mapping on neural cell images of the whole brain
US20240216510A1 (en) * 2021-04-20 2024-07-04 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptors to sialyl-tn glycan antigen
WO2022224242A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
AU2022262421A1 (en) * 2021-04-23 2023-10-19 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US20250186494A1 (en) * 2022-02-10 2025-06-12 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤(NK)细胞接合物
CN116102652B (zh) * 2022-10-11 2024-05-31 上海交通大学医学院附属瑞金医院 一种抗rcp抗体及其制备方法
WO2024193794A1 (en) * 2023-03-17 2024-09-26 Danmarks Tekniske Universitet Combotope antibody libraries
CN120882741A (zh) 2023-03-17 2025-10-31 丹麦科技大学 组合表位抗体库
WO2025006452A2 (en) * 2023-06-26 2025-01-02 Sri International NEU5GC-LEWISa-TARGETING MOLECULES AND USES THEREOF IN CANCER
WO2026032010A1 (en) * 2024-08-05 2026-02-12 The Hong Kong University Of Science And Technology Glycan-targeting protein aggregation therapy

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US715A (en) 1838-04-28 Improvement in water-wheels
US5807A (en) 1848-09-26 Brake fob cabs
US823244A (en) 1906-01-18 1906-06-12 Emerson Mfg Co Wheeled plow.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US6872868B1 (en) 1981-06-12 2005-03-29 Ohio University Transgenic mammals
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US4695198A (en) 1986-05-23 1987-09-22 Chevron Research Company Lip-type sealing system for a removable bottom founded structure
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CA1340456C (en) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
CA1340927C (en) 1987-10-09 2000-03-14 Peter S. Linsley Method for increasing the sensitivity of assays for target ligand
IT1212041B (it) 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
JPH02486A (ja) 1987-11-13 1990-01-05 Mect Corp 遊離n−アセチルノイラミン酸を認識するモノクローナル抗体
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5951983A (en) 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5710038A (en) 1994-11-25 1998-01-20 Universite De Montreal Primary cultures of normal and tumoral human ovarian epithelium
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
AU720802B2 (en) 1996-07-03 2000-06-15 Millenium Pharmaceuticals, Inc. Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
CA2304208A1 (en) 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
CA2311729A1 (en) 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US20020012660A1 (en) 1999-03-04 2002-01-31 Alan Colman Method of preparing a somatic cells for nuclear transfer
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
AU5744800A (en) 1999-06-16 2001-01-02 Biocrystal Limited Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells
EP1244705B1 (en) 1999-12-06 2010-01-27 Agensys, Inc. Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
EP1237581A1 (en) 1999-12-17 2002-09-11 Gene Therapy Systems, Inc. Use of cationic lipids for intracellular protein delivery
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
WO2002067849A2 (en) 2001-02-26 2002-09-06 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
GB0108165D0 (en) 2001-03-31 2001-05-23 Univ Manchester Intracellular analysis
JP2004533242A (ja) 2001-04-30 2004-11-04 アールビーシー バイオテクノロジー, インコーポレイテッド 異種移植のための改変された器官および細胞
CA2445746C (en) 2001-04-30 2012-09-18 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
KR100486784B1 (ko) 2001-05-22 2005-04-29 김하형 솔비나무로 부터 추출된 렉틴 단백질, 그의 제조방법 및용도
WO2002094199A2 (en) 2001-05-24 2002-11-28 Immucom Inc. METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
US6814734B2 (en) 2001-06-18 2004-11-09 Sdgi Holdings, Inc, Surgical instrumentation and method for forming a passage in bone having an enlarged cross-sectional portion
CA2453662A1 (en) 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
WO2003016329A2 (en) 2001-08-17 2003-02-27 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
WO2003040185A2 (de) 2001-11-09 2003-05-15 Hexal Biotech Forschungsgmbh Anti-n-glykolyl-neuraminsäure-antikörper und ihre verwendung zur bestimmung von glykoproteinen
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
GB0201611D0 (en) 2002-01-24 2002-03-13 Grosveld Frank Transgenic animal
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
GB0226723D0 (en) 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003222171A1 (en) 2002-04-05 2003-10-27 Selective Genetics, Inc. Compositions and methods for portal specific gene delivery and treatment of infection
PT2332989E (pt) 2002-05-22 2015-08-05 Esbatech Alcon Biomed Res Unit Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004046188A2 (en) 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
GB0226731D0 (en) 2002-11-15 2002-12-24 Medical Res Council Method for generating immunoglobulin genes
ITRM20020588A1 (it) 2002-11-21 2004-05-22 Lay Line Genomics Spa Metodo per isolare anticorpi intracellulari neutralizzanti di interazioni proteiche.
EP1482309A1 (en) 2003-05-07 2004-12-01 Institut Curie Means for detecting protein conformation and applications thereof
CN1835951B (zh) 2003-07-11 2010-06-02 沃尼尔·朗伯有限责任公司 选择性cdk4抑制剂的羟乙基磺酸盐
US7682794B2 (en) 2003-07-15 2010-03-23 The Regents Of The University Of California Methods for detecting and analyzing N-glycolylneuraminic acid (Neu5Gc) in biological materials
ITMI20031909A1 (it) 2003-10-03 2005-04-04 Keryos Spa Linee cellulari di mammifero modificate per la produzione di glicoproteine ricombinanti.
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005088310A2 (en) 2004-03-05 2005-09-22 The Scripps Research Institute High throughput glycan microarrays
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
AU2005258281A1 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
US7638467B2 (en) 2004-08-03 2009-12-29 Intevep, S.A. Reversible gelling system and method using same during well treatments
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006068758A2 (en) 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
WO2006133356A2 (en) 2005-06-08 2006-12-14 The Regents Of The University Of California Elimination of n-glycolylneuraminic acid from mammalian products for human use
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
HUE039865T2 (hu) 2005-12-20 2019-02-28 Sbi Biotech Co Ltd Anti-ILT7 antitest
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
EP1808442B1 (en) 2006-01-13 2011-05-11 Institut Pasteur Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
JPWO2007116779A1 (ja) 2006-03-31 2009-08-20 持田製薬株式会社 新規血小板活性化マーカー及びその測定方法
US20070265170A1 (en) 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
WO2008040362A2 (en) 2006-10-04 2008-04-10 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
US20100143371A1 (en) 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
US20100104572A1 (en) 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
WO2009018438A1 (en) 2007-07-31 2009-02-05 Cornell Research Foundation, Inc. Protein discovery using intracellular ribosome display
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
WO2009035494A2 (en) 2007-07-30 2009-03-19 The Scripps Research Institute Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
FI20070853A0 (fi) 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US20120027813A1 (en) 2008-02-22 2012-02-02 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines for pediatric use
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
US8298773B2 (en) 2008-05-02 2012-10-30 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
FI20095418A0 (fi) 2009-04-16 2009-04-16 Suomen Punainen Risti Veripalv Kryptinen subpopulaatio
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
US20120045816A1 (en) 2008-09-09 2012-02-23 Sialix, Inc. Novel Glycosylated Polypeptides
CN102197131A (zh) 2008-09-09 2011-09-21 加利福尼亚大学董事会 通过代谢竞争除去污染性的非人唾液酸
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US20100178292A1 (en) 2009-01-12 2010-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cryptic glycan markers and applications thereof
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
CN102448469A (zh) 2009-05-28 2012-05-09 摩萨纳医疗有限公司 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2275442A1 (en) 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
EP2287202A1 (en) * 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
EP2524233A4 (en) 2010-01-15 2013-07-31 Univ California COMPOSITIONS AND METHOD FOR DETECTING CANCER
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2565268A4 (en) 2010-04-28 2013-10-09 Shionogi & Co NEW MUC1 ANTIBODY
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103209701B (zh) 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
CN103501815B (zh) 2010-10-08 2016-09-28 希望之城公司 针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
DK2661492T3 (en) 2011-01-06 2018-01-15 Univ Johns Hopkins Method for Preparing Recombinant Glycoproteins with Increased Circuit Half Life in Mammalian Cells
US20130030040A1 (en) 2011-02-01 2013-01-31 Hibm Research Group, Inc. Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
US20140005069A1 (en) 2011-03-01 2014-01-02 Glycosensors And Diagnostics, Llc. Glycoprofiling with multiplexed suspension arrays
WO2012133572A1 (ja) 2011-03-30 2012-10-04 国立大学法人富山大学 形質細胞または形質芽細胞の選択方法、目的抗原特異的な抗体の製造方法、新規モノクローナル抗体
CA2837840C (en) 2011-06-10 2020-08-04 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
WO2013033420A1 (en) 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
KR102276792B1 (ko) 2011-10-10 2021-07-15 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6441079B2 (ja) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
US20130177579A1 (en) 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
WO2013151649A1 (en) * 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014030780A1 (en) 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
EP2935331B1 (en) 2012-12-24 2018-02-28 AbbVie Inc. Prolactin receptor binding proteins and uses thereof
EP2752487A1 (en) 2013-01-03 2014-07-09 Sanofi Intracellular phenotypic screening
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
CN105530959B (zh) 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
ES2800602T3 (es) 2013-07-23 2021-01-04 Ohio State Innovation Foundation Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72)
WO2015048748A1 (en) 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
US20160264684A1 (en) 2013-10-10 2016-09-15 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
BR112016020287B1 (pt) 2014-03-04 2022-06-28 Sigma-Aldrich Co. Llc Uso de uma linhagem celular de ovário de hamster chinês (cho) geneticamente modificada, composição e métodos para reduzir o risco de contaminação viral de um sistema de produção biológico e para reduzir ou prevenir a contaminação viral de um produto de proteína recombinante
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
AU2015308854A1 (en) 2014-08-27 2017-03-02 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
US20170305950A1 (en) 2014-10-10 2017-10-26 Siamab Therapeutics, Inc. Glycan analysis and profiling
US20180280504A1 (en) 2014-10-10 2018-10-04 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) * 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
US20200041517A1 (en) 2015-06-12 2020-02-06 Seattle Genetics, Inc. Compositions and methods for targeting cancer stem cells
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2017132486A1 (en) 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
WO2018094144A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Compositions and methods for treating cancer
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE

Similar Documents

Publication Publication Date Title
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
JP2022163013A (ja) グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
JP2020182492A (ja) 抗cd137抗体
CN114206931B (zh) 抗pd-1抗体及其用途
JP2016523265A (ja) 抗pd−1抗体およびその応用
AU2014361473A1 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TW201942130A (zh) 結合至ssea4的單株抗體及其用途
WO2010132532A1 (en) B cell surface reactive antibodies
CN108623685A (zh) 抗ox40抗体及其用途
CN117120469A (zh) 抗tnfr2人源化抗体及其用途
JP7009642B2 (ja) 抗-vista抗体及びその用途
CN106999576A (zh) 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
CN113788894A (zh) 靶向人Claudin18.2蛋白的单克隆抗体及其应用
WO2018129090A1 (en) Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3
KR20210027254A (ko) Tim-3에 대한 항체 및 그의 용도
TW201927819A (zh) 雙專一性抗體及製造與使用其的方法
CN105985435B (zh) 全人源her2抗体的突变抗体及其编码基因和应用
CN120344653A (zh) 成纤维细胞活化蛋白(fap)car-恒定型自然杀伤t细胞及其用途
TW202340240A (zh) 多特異性抗體及其藥物用途
CN118317788B (zh) Tnfr2结合分子及其用途
WO2024141027A1 (zh) 一种双特异性抗体及其应用
CN120659810A (zh) 抗cdh6的抗体及其用途
CN113087796B (zh) 一种抗pd-l1抗体及其应用
CN113366104A (zh) mRNA展示抗体文库和方法
TWI793451B (zh) 個人化癌症免疫治療